BenevolentAI Investor Conference Presentation Deck

Multiple value inflection points expected H2 2022 BEN-2293 Atopic Dermatitis BEN-8744 Ulcerative Colitis BEN-28010 Glioblastoma multiforme BEN-9160 Amyotrophic lateral sclerosis Pipeline depth and progression AZ Collaboration Other Platform Collaborations I Complete Phase lla clinical study File Clinical Trial Application (CTA) late 2022 Commence IND enabling studies Move at least 1 project into lead opt & Initiate 2 - 4 new drug discovery programmes 2023 I Full data package available Q1 2023 Out-licensing Begin Phase I study early 2023 Submit Clinical Trial Application (CTA) Commence IND enabling studies Submit Clinical Trial Application (CTA) Expect to add 4-6 names drug programmes 2024 Discussions with a number of parties ongoing 1 Phase I data package early 2024, with Phase II to follow shortly after Initiate Phase I study Initiate Phase I study Aim to progress 1-2 CTA/IND stage drug candidates every year Five targets selected and advancing (3 x IPF and 2x CKD) - extension of collaboration into two new disease areas (SLE and Heart Failure) Benevolent 17

View entire presentation